KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Payables (2019 - 2025)

Historic Payables for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $41.4 million.

  • Royalty Pharma's Payables rose 8778.05% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year increase of 8778.05%. This contributed to the annual value of $13.4 million for FY2024, which is 1183.65% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Payables is $41.4 million, which was up 8778.05% from $20.2 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Payables peaked at $41.4 million during Q3 2025, and registered a low of $5.6 million during Q4 2021.
  • Moreover, its 5-year median value for Payables was $12.2 million (2022), whereas its average is $15.1 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 7266.78% in 2021, then soared by 30309.86% in 2024.
  • Over the past 5 years, Royalty Pharma's Payables (Quarter) stood at $5.6 million in 2021, then surged by 40.68% to $7.9 million in 2022, then skyrocketed by 91.82% to $15.2 million in 2023, then dropped by 11.84% to $13.4 million in 2024, then soared by 209.76% to $41.4 million in 2025.
  • Its last three reported values are $41.4 million in Q3 2025, $20.2 million for Q2 2025, and $37.6 million during Q1 2025.